Saturday, 20 June 2026

Vol. 1 · No. 18 Saturday, 20 June 2026 “The record, not the rumour.”

In this edition

A landmark Bayesian platform trial enrolling 1,303 patients settles four decades of debate over MSSA bacteremia therapy, finding cefazolin noninferior to antistaphylococcal penicillins on 90-day mortality while cutting acute kidney injury by a third. The FDA approves tebipenem pivoxil — the first oral carbapenem in U.S. history — for complicated urinary tract infections after the PIVOT-PO trial demonstrated noninferiority to IV imipenem-cilastatin. An FDA advisory panel votes unanimously 9–0 to recommend Moderna's mRNA influenza vaccine for adults 50 and older, setting a PDUFA target of August 5. The African Union mobilizes $910 million in pledges for the BDBV Ebola response, with African member states committing $80 million of the total. And an FDA-authorized neuromodulation device for PTSD reaches the market with its pivotal trial still unpublished.

Clinical Trials

Cefazolin Matches Antistaphylococcal Penicillins on Survival in MSSA Bacteremia

A 1,303-patient Bayesian platform trial settles four decades of clinical debate: the cheaper, more forgiving beta-lactam performs as well as the guideline gold standard on 90-day mortality — and comes with a kidney-sparing advantage.

Clinical Trials Desk · 2 min read

For four decades, clinicians treating Staphylococcus aureus bacteremia faced a question without a rigorous randomized answer: could cefazolin — cheaper, easier to administer, and anecdotally more renal-sparing than the guideline-preferred antistaphylococcal penicillins (ASP) — substitute for nafcillin, oxacillin, or flucloxacillin? The SNAP trial, reported this week in the New England Journal of Medicine, has now produced the most definitive evidence yet: on survival, cefazolin does not lose.

Trial Design and Enrollment

Continue reading →

Also leading today

Opinion

Cefazolin Earns Its Place — With Caveats the Data Can't Yet Answer

The SNAP result is the strongest trial evidence yet for cefazolin in MSSA bacteremia. What it cannot do is resolve every case a hospital pharmacist will face on Monday morning.

Clinical Analysis · 2 min

FDA & Regulatory

FDA Approves First Oral Carbapenem in U.S. History for Complicated Urinary Tract Infections

Tebipenem pivoxil (Utebzi) clears on PIVOT-PO noninferiority data — oral versus IV imipenem-cilastatin — opening a step-down path from hospital to outpatient for multidrug-resistant Enterobacteriaceae.

FDA & Regulatory Desk · 2 min

In brief

FDA & Regulatory FDA Advisory Panel Votes 9–0 to Back Moderna's mRNA Flu Vaccine — PDUFA August 5 VRBPAC unanimously recommended MFLUSIVA (mRNA-1010) for adults 50 and older via two pathways — traditional approval for ages 50–64, accelerated approval for 65+ — in the first advisory review of an mRNA influenza vaccine.
Digital Health & AI Colorado Enacts Laws Barring AI-Only Coverage Denials and Unsupervised AI Psychotherapy HB 26-1139 requires clinician review of AI-assisted prior-authorization denials. HB 26-1195 mandates professional supervision of AI-delivered mental health care. Both join a growing body of state health-AI law — not pioneer it.
Devices & Diagnostics FDA Authorizes First Neuromodulation Device for PTSD, but the Pivotal Trial Is Unpublished Neurovalens's Modius Spero receives De Novo clearance for PTSD — a first in class that reaches the market with its pivotal efficacy data still in regulatory files, not peer-reviewed literature.
Public Health African Union Mobilizes $910 Million for BDBV Ebola Response; African Members Pledge $80 Million A June 16 AU High-Level Presidential Meeting produced $910 million in total pledges for the ongoing Bundibugyo ebolavirus outbreak — $80 million from African member states, $830 million from external partners — as WHO confirms 234 confirmed deaths and no licensed BDBV vaccine exists.
Research IMbrave050 Phase 3 Adjuvant HCC Trial Reaches Full Completion — OS Data Remain Immature The second interim analysis of atezolizumab plus bevacizumab versus active surveillance in resected hepatocellular carcinoma shows an updated recurrence-free survival HR of 0.90 but an immature OS signal with a point estimate numerically favoring surveillance.
Biotech Business FDA Issues Complete Response Letter for Cytisinicline, Citing Manufacturing Deficiencies Achieve Life Sciences' NDA 217082 receives a CRL on manufacturing grounds after two Phase 3 trials (ORCA-2, ORCA-3; combined n=1,602) demonstrated efficacy — leaving clinical data intact but approval contingent on GMP remediation.

← The archive